Related Experiment Video
Updated: Apr 9, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
[Chronic heart failure : current guideline recommendations and innovations]
1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., Geb. 40, 66421, Homburg/Saar, Deutschland, sebastian.ewen@uks.eu.
Insights
This review highlights 2014 innovations in chronic heart failure therapy, including updated guidelines and new medications like ARNI (angiotensin receptor-neprilysin inhibitors). It also covers managing comorbidities such as atrial fibrillation and hyperkalemia.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Chronic heart failure (CHF) is a global health concern with rising prevalence.
- Standardized, evidence-based treatment is crucial due to high morbidity and mortality.
- European Society of Cardiology (ESC) guidelines provide a framework for CHF management.
Purpose:
- To provide an overview of key innovations in chronic heart failure management from 2014.
- To highlight updates to established therapies and introduce novel pharmacological agents.
- To discuss new insights into managing common comorbidities in CHF patients.
Summary:
- Reviews advancements in established CHF medications, including beta-blockers and mineralocorticoid receptor antagonists.
- Introduces the novel drug class Angiotensin Receptor-Neprilysin Inhibitors (ARNI).
- Addresses updated management strategies for comorbidities like atrial fibrillation and hyperkalemia.
Impact:
- Facilitates the adoption of updated, evidence-based treatment protocols for chronic heart failure.
- Informs clinicians about new therapeutic options, potentially improving patient outcomes.
- Enhances the comprehensive management of complex CHF patients with multiple comorbidities.
Abstract:
Chronic heart failure is one of the most common chronic diseases worldwide with increasing prevalence and incidence. Due to the high morbidity and mortality a standardized and evidence-based therapy is essential. The present article gives an overview of the innovations from 2014 based on the current guidelines of the European Society of Cardiology. First, improvements of established medication regimens regarding beta blockers, mineralocorticoid receptor antagonists and treatment options for heart rate reduction and disease management programs will be explained. Second, new pharmacological developments, such as the new substance class of angiotensin receptor blockers and neprilysin inhibitors (ARNI), will be presented. Finally, new insights into common comorbidities of chronic heart failure patients, such as atrial fibrillation and hyperkalemia will be discussed.
More Related Videos
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Pathophysiology of Heart Failure

